SCHEMBL3015282

SCHEMBL3015282

O=S(=O)(c1ccc(Cl)cc1Cl)N1CCN(c2nc(Cc3ccc(Cl)cc3Cl)cs2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 2/20 0.46
HSD11B1 P28845 2/20 0.44
KDM2B Q8NHM5 1/20 0.41
GAA P10253 1/20 0.40
AR P10275 1/20 0.40
POLB P06746 1/20 0.40
LPAR1 Q92633 1/20 0.40
LPAR2 Q9HBW0 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPT P10636 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MEN1 O00255 2/20 0.38
LMNA P02545 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPK1 P28482 1/20 0.38
TSHR P16473 2/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010684 0.94 TRPV4 (0.42) TRPV4HSD11B1KDM2BGAAAR
SCHEMBL3014669 0.94 ALDH1A1 (0.44) TRPV4HSD11B1KDM2BGAAPOLB
SCHEMBL3016167 0.93 CHRM4 (0.44) TRPV4HSD11B1POLBALDH1A1MAPT
SCHEMBL3127462 0.93 ALDH1A1 (0.48) KDM2BGAAARPOLBALDH1A1
SCHEMBL3021382 0.90 TRPV4 (0.48) TRPV4HSD11B1KDM2BGAAAR
SCHEMBL3017406 0.90 EPHX2 (0.44) TRPV4GAAPOLBLPAR1LPAR2
SCHEMBL3009094 0.89 TRPV4 (0.47) TRPV4HSD11B1KDM2BGAAAR
SCHEMBL3002640 0.89 POLB (0.52) HSD11B1GAAPOLBALDH1A1MAPT
SCHEMBL3014501 0.89 ALDH1A1 (0.43) HSD11B1GAAPOLBRAB9AALDH1A1
SCHEMBL3006382 0.89 TSHR (0.44) TRPV4HSD11B1GAAPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TRPV4 2844/4885HSD11B1 1034/4885KDM2B 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.